Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis

European Respiratory Journal

Volumn 49, Issue 4, 2017, Pages

  Forsman, Lina Davies ^a,b   Bruchfeld, Judith ^a,b   Alffenaar, Jan Willem C ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG MONITORING; DRUG TREATMENT FAILURE; HUMAN; LETTER; MEDICATION COMPLIANCE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; DRUG EFFECT; DRUG RESISTANCE;

ANTITUBERCULAR AGENTS; DRUG MONITORING; DRUG RESISTANCE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85027890001     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00173-2017     Document Type: Letter

References (11)

1. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1049–1063.
2. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642–1651.
3. Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
4. Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951–1959.
5. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888–894.
6. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63: e147–e195.
7. Ghimire S, Bolhuis MS, Sturkenboom MG, et al. Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. Eur Respir J 2016; 47: 1867–1869.
8. Foongladda S, Banu S, Pholwat S, et al. Comparison of TaqMan® Array Card and MYCOTB™ with conventional phenotypic susceptibility testing in MDR-TB. Int J Tuberc Lung Dis 2016; 20: 1105–1112.
9. Mpagama SG, Ndusilo N, Stroup S, et al. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2014; 58: 782–788.
10. Ghimire S, Van’t Boveneind-Vrubleuskaya N, Akkerman OW, et al. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. J Antimicrob Chemother 2016; 71: 2691–2703.
11. Alffenaar JC, Tiberi S, Verbeeck RK, et al. Therapeutic drug monitoring in tuberculosis: practical application for physicians. Clin Infect Dis 2017; 64: 104–105.